Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trudell Medical Ltd.

Latest From ChemGenex Pharmaceuticals Ltd.

Complexities of Precision Medicine: Managing Multiple Rx/Dx Combos in the Same Class

What happens when multiple targeted therapies are approved by FDA, each with a unique companion diagnostic for the same biomarker? The health care system is ill-equipped to deal with that scenario, putting patients at risk if the wrong test is used to guide a treatment decision. Industry has one solution: an analytical comparison of various diagnostic assays, starting with the anti-PD-L1 immunotherapy class.

BioPharmaceutical Regulation

Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More

Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.

BioPharmaceutical Deals

IND Promotion Quandary Again Trips Up Burzynski Research Institute

The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.

BioPharmaceutical United States

Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine

Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.

BioPharmaceutical United States
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register